Table 1.
Subject characteristics.
| Group | CN (N = 56) | MCI (N = 78) | AD (N = 41) | total (N = 175) | p-value |
|---|---|---|---|---|---|
| Age in years | 75.5 ± 4.8 | 74.7 ± 7.93 | 74.5 ± 8.46 | 74.9 ± 7.22 | n.s. |
| Gender | 0.003 | ||||
| female (N) | 35 (62.5 %) | 29 (37.2 %) | 26 (63.4) | 90 (51.4 %) | |
| male (N) | 21 (37.5 %) | 49 (62.8 %) | 15 (36.6 %) | 85 (48.6 %) | |
| BMI in | 26.6 ± 4.4 | 25.1 ± 3.0 | 24.5 ± 3.9 | 25.4 ± 3.8 | 0.01 |
| Weight in kg | 74.4 ± 13.78 | 74.5 ± 12.50 | 67.8 ± 14.81 | 72.8 ± 13.8 | 0.02 |
| MMSE | 29.2 ± 0.8 | 25.7 ± 2.6 | 21.4 ± 3.5 | 25.8 ± 3.8 | 0<.0001 |
| CDR | 0 ± 0 | 0.5 ± 0 | 0.67 ± 0.24 | 0.38 ± 0.29 | 0<.0001 |
| t-tau in pg/ml | 75 ± 31 (N = 25) | 95 ± 59 (N = 44) | 127 ± 40 (N = 23) | 97 ± 52 (N = 92) | 0.001 |
| p-tau in pg/ml | 26 ± 13 (N = 25) | 34 ± 19 (N = 46) | 43 ± 17 (N = 24) | 34 ± 18 (N = 95) | 0.003 |
| Subgroups for APOE-allele-status and β-Amyloid-positivity | |||||
| APOE ε4 | N = 56 | N = 78 | N = 41 | N = 175 | 0.002 |
| ε4-negative (N) | 39 (69.6 %) | 37 (47.4 %) | 14 (34.1 %) | 90 (51.4 %) | |
| ε4-positive (N) | 17 (30.4 %) | 41 (52.6 %) | 27 (65.9 %) | 85 (48.6 %) | |
| AB | N = 25 | N = 46 | N = 24 | total (N = 95) | 0.0004 |
| AB- (N) | 17 (68 %) | 13 (28.3 %) | 4 (16.7 %) | 34 (35.8 %) | |
| AB+ (N) | 8 (32 %) | 33 (71.7 %) | 20 (83.3 %) | 61 (64.2 %) | |
Subject characteristics with p-values indicating significance of group differences. Data is expressed as mean ± SD except for Gender, APOE-allele status, β-Amyloid-positivity. Subject count is indicated as N. AB β-Amyloid 1–42, AB + Aβ-positive, AB- Aβ-negative, AD Alzheimer’s Disease, APOE apolipoprotein E, BMI body mass index, CDR clinical dementia rating, CN cognitively normal, MCI mild cognitive impairment, MMSE mini-mental-status exam, n.s. not significant, SD standard deviation.